N/A N=37 Biobehavioral Pathways Underlying Alcohol Use and Health
Alcohol Use Disorder · Liver Diseases
Primary: Percentage of Screen Eligible Who Enroll — 28; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=134 Records for Alcohol Care Enhancement
Alcohol Use Disorder (AUD)
Primary: Percent of New Alcohol Use Disorder (AUD) Diagnosis Episodes That Meet Criteria for AUD Treatment Engagement Among Patients With a New AUD Diagnosis Who Are Empaneled to…
N/A N=3 Pilot Human Laboratory Study of Alcohol Approach Bias Modification (AABM) for Alcohol Use Disorder (AUD)
Alcohol Use Disorder
Primary: Recruitment Feasibility — 3 Participants
N/A N=60 Acute Alcohol Response In Bipolar Disorder: a fMRI Study
Bipolar Disorder · Alcohol Drinking · Alcohol Use Disorder
Primary: Level of Intoxication (Subjective Response) on Each Condition Day After Drinking Relative to How They Felt When Arriving to the Lab on That Respective Day )Prior to…
Phase 2 N=27 Effects of Cannabidiol in Alcohol Use Disorder
Alcohol Use Disorder
Primary: Trough CBD Plasma Levels — 0; 0.7 CBD (ng/mL)
N/A N=75 Transdiagnostic CBT for Comorbid Alcohol Use and Anxiety Disorders
Alcohol Use Disorder · Anxiety Disorders
Primary: Mean Number of Drinks Consumed Per Week — 40.82; 29.62; 12.12; 23.86 Standard Drinking Units per Week — p=0.002
Phase 2 N=12 Modafinil for the Treatment of Alcohol Use Disorders
Alcohol Use Disorder
Primary: Time to Relapse — 16; 43 days
N/A N=2 Deep Brain Stimulation for Alcohol Use Disorder
Alcohol Use Disorder
Primary: Number of Serious Adverse Events (Safety and Tolerability) — 1; 1 Adverse Events
N/A N=185 Pioglitazone for the Treatment of Alcohol Use Disorder
Alcohol Use Disorder
Primary: Heavy Drinking Days Per Week Change — -1.76; -2.3 Mean heavy drinking days per week
Phase 2 N=48 Semaglutide for Alcohol Use Disorder
Alcohol Use Disorder · Cigarette Smoking
Primary: Change in Alcohol Consumed — -32.72; -6.95 grams
Phase 2 N=102 Ibudilast for the Treatment of Alcohol Use Disorder
Alcohol Use Disorder
Primary: Percent Heavy Drinking Days — 67.4777; 65.65447; 53.88376; 42.96028 percent of heavy drinking days
Phase 3 N=40 Glutamatergic Modulation of Disordered Alcohol Use
Alcohol Dependence
Primary: Percentage of Participants Demonstrating Alcohol Abstinence in the Control (Midazolam) Group Versus the Active (Ketamine) Group — 68.6; 98.6 percentage of participants
Phase 2 N=60 Human Laboratory Study of ASP8062 for Alcohol Use Disorder
Alcohol Use Disorder · Alcohol Drinking · Alcohol Use Disorder (AUD)
Primary: Alcohol Craving — 6.44; 6.26 score on a scale — p=0.784
Phase 3 N=75 Aripiprazole for Bipolar Disorder and Alcohol Use Disorder
Bipolar Disorder · Alcoholism · Alcohol Abuse
Primary: Timeline Follow Back (TLFB) — -0.82; -0.71 drinks per drinking day
N/A N=285,304 Sustaining Patient-centered Alcohol-related Care
Alcohol, Drinking · Alcohol Use Disorder
Primary: Brief Alcohol Counseling Rate — 57; 11 participants per 10,000 with visits — p=<.001
N/A N=84 Mindfulness-Based Intervention and Transcranial Direct Current Brain Stimulation to Reduce Heavy Drinking
Alcohol Drinking · Alcohol Intoxication · Alcoholism
Primary: Drinks Per Drinking Day — 5.12; 5.64; 4.95; 5.48 drinks per drinking day
Phase 1 N=26 Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics
Alcohol Dependence
Primary: Craving for Alcohol in Alcohol Dependence With Citalopram Compared to Placebo — 21; 30.4; 10.8; 10.6 score on a scale
Phase 2 N=21 Manipulating Ghrelin Signaling Via GOAT Inhibition in Alcohol Use Disorder
Alcohol Use Disorder
Primary: Number of Participants With Adverse Events (AEs) — 18; 15 Participants
Phase 2 N=255 A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
Schizophrenia · Alcohol Use Disorder
Primary: Number of Participants With Independent Adjudication Committee (IAC) Adjudicated Event of Exacerbation of Disease (EEDS) — 25; 29; 87; 88 Participants — p=0.746
Phase 2 N=27 Collaborative Care for Alcohol Use Disorders in the Patient-centered Medical Home
Alcohol-Related Disorders · Alcohol Drinking · Alcoholism
Primary: Weekly Change in Drinking — -11.4; -22.2; -39.6; -29.3 score on a scale
Phase 3 N=155 Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy
Alcohol Use Disorder
Primary: Change in Heavy Drinking Days Per Week for Dutasteride vs. Placebo Groups — -2.24; -1.41 Heavy Drinking Days per week — p=0.012
N/A N=35 Brief Family-involved Treatment for Alcohol Use Disorder
Alcohol Use Disorder
Primary: Form-90 Timeline Followback Interview — .78; .64 proportion of days abstinent
Phase 2 N=52 Ibudilast and Withdrawal-Related Dysphoria
Alcohol Use Disorder
Primary: Negative Affect — 2.91; 2.47 units — p=.62
Phase 2 N=36 Cannabidiol in Youth Alcohol Use Disorder
Alcohol Use Disorder
Primary: Concentrations of Glx (i.e., Glutamate + Glutamine) — 18.76; 18.57 mmol/kg — p=0.33
N/A N=8 Examining the Effectiveness of Deep TMS in Veterans With Alcohol Use Disorder
Alcohol Use Disorder (AUD) · Transcranial Magnetic Stimulation
Primary: Number of Participants With Relapse to Alcohol 6 Months After Treatment — 3 Participants
N/A N=131 Neurobiological Responses in Alcoholism and Early Trauma
Alcohol Use Disorder · Early Trauma Complications
Primary: Brain Response — .015; .010; -.013; .08 unitless — p=<0.05
N/A N=558 Mobile Health for Alcohol Use Disorders in Clinical Practice
Alcohol Drinking · Telemedicine
Primary: Percentage of Heavy Drinking Days, PHDD — 24.4; 21.4; 21.3 percentage of heavy drinking days — p=0.688
Phase 2 N=182 Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD)
Post Traumatic Stress Disorder (PTSD) · Addiction · Alcohol Abuse
Primary: Change in Alcohol Use Severity — -3.406; -3.934 standard drinks per day
Phase 2 N=4 Pilot Human Lab Study of Lacosamide in Alcohol Use Disorder (AUD)
Alcohol Use Disorder
Primary: Recruitment Feasibility (Time, in Months,) Required to Recruit, Screen and Conduct the Study Procedures — 7.0 months
Phase 2 N=100 Intranasal Oxytocin for the Treatment of Alcohol Use Disorder
Alcohol Use Disorder · Alcohol Misuse
Primary: Weekly Percentage of Heavy Drinking Days — 51.5; 52.9 percentage of days per week